Skip to content. Skip to main navigation.
A key to forestalling the development of preventable cardiometabolic diseases such as type 2 diabetes is being able to identify those individuals at greatest risk, so that scarce healthcare resources can be targeted toward the patients who will benefit most from early and aggressive intervention.
Tethys creates and commercializes novel blood tests that utilize a highly accurate, multi-marker measurement technology to assess time-based disease risk.
More accurate risk assessment empowers physicians to make better-informed patient management decisions that can delay and even prevent the onset of chronic conditions.